Wactawski-Wende J, Anderson G L
* University at Buffalo , Buffalo, New York.
Climacteric. 2015 Jun;18(3):343-5. doi: 10.3109/13697137.2015.1019244.
The impact of the findings from the Women's Health Initiative trial of estrogen plus progestin cannot be attributed to any real or imagined conflicts of interest between government, researchers, and journals. Rather, the findings overturned decades of dogma in part promoted by the pharmaceutical industry, and the reaction to these unexpected findings was in direct proportion to their importance in reversing a misguided practice of prescribing the drug for chronic disease prevention. The findings have been widely accepted, as shown by the sustained subsequent reduction in prescriptions. However, conflicts of interest may influence a minority unwilling to accept the findings. The decrease in the use of a drug with an adverse risk profile for prevention of chronic disease is a public good.
妇女健康倡议雌激素加孕激素试验的结果所产生的影响，不能归因于政府、研究人员和期刊之间任何实际的或想象中的利益冲突。相反，这些结果推翻了制药行业在一定程度上所推动的几十年的教条，而对这些意外结果的反应与它们在扭转将该药物用于慢性病预防的错误做法方面的重要性成正比。这些结果已被广泛接受，后续处方量持续减少就表明了这一点。然而，利益冲突可能会影响少数不愿接受这些结果的人。减少使用具有不良风险特征的药物来预防慢性病是一项公益。
